1. Home
  2. STTK vs SRFM Comparison

STTK vs SRFM Comparison

Compare STTK & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • SRFM
  • Stock Information
  • Founded
  • STTK 2016
  • SRFM 2011
  • Country
  • STTK United States
  • SRFM United States
  • Employees
  • STTK N/A
  • SRFM N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • SRFM Transportation Services
  • Sector
  • STTK Health Care
  • SRFM Consumer Discretionary
  • Exchange
  • STTK Nasdaq
  • SRFM Nasdaq
  • Market Cap
  • STTK 54.4M
  • SRFM 62.8M
  • IPO Year
  • STTK 2020
  • SRFM 2023
  • Fundamental
  • Price
  • STTK $1.16
  • SRFM $3.30
  • Analyst Decision
  • STTK Hold
  • SRFM Hold
  • Analyst Count
  • STTK 3
  • SRFM 2
  • Target Price
  • STTK $2.00
  • SRFM $3.40
  • AVG Volume (30 Days)
  • STTK 332.9K
  • SRFM 625.6K
  • Earning Date
  • STTK 11-14-2024
  • SRFM 11-14-2024
  • Dividend Yield
  • STTK N/A
  • SRFM N/A
  • EPS Growth
  • STTK N/A
  • SRFM N/A
  • EPS
  • STTK N/A
  • SRFM N/A
  • Revenue
  • STTK $6,435,000.00
  • SRFM $118,212,000.00
  • Revenue This Year
  • STTK $313.04
  • SRFM $102.41
  • Revenue Next Year
  • STTK N/A
  • SRFM $47.46
  • P/E Ratio
  • STTK N/A
  • SRFM N/A
  • Revenue Growth
  • STTK 382.75
  • SRFM 198.78
  • 52 Week Low
  • STTK $0.94
  • SRFM $0.90
  • 52 Week High
  • STTK $11.76
  • SRFM $11.83
  • Technical
  • Relative Strength Index (RSI)
  • STTK 44.02
  • SRFM 49.61
  • Support Level
  • STTK $1.07
  • SRFM $2.76
  • Resistance Level
  • STTK $1.38
  • SRFM $4.50
  • Average True Range (ATR)
  • STTK 0.12
  • SRFM 0.82
  • MACD
  • STTK 0.01
  • SRFM -0.15
  • Stochastic Oscillator
  • STTK 27.88
  • SRFM 16.43

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

About SRFM Surf Air Mobility Inc.

Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.

Share on Social Networks: